Search Results for "Rapivab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Rapivab. Results 1 to 3 of 3 total matches.
See also: peramivir
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
Peramivir – Rapivab (BioCryst)
200 mg/20 mL single-use vials
IV
▪ FDA-approved for treatment ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5 doi:10.58347/tml.2024.1717d | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
Peramivir – Rapivab (BioCryst)
200 mg/20 mL single-use
vials
Treatment:
6 months-12 yrs: 12 mg/kg (max ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
(Relenza) within
48 hours before, peramivir (Rapivab) within 5 days
before, or baloxavir marboxil ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 doi:10.58347/tml.2024.1711a | Show Introduction Hide Introduction